An international research collaboration involving Bar-Ilan University in Israel, the Icahn School of Medicine at Mount Sinai in the US, and partners from Canada, has yielded significant results in the fight against Alzheimer's disease. The study, published in the journal Alzheimer's & Dementia, introduces an innovative imaging technology capable of identifying the mysterious cause behind the early stages of Alzheimer's disease.
Until now, Alzheimer's diagnosis has been hindered by the presence of amyloid-beta oligomers, small toxic protein clumps that begin damaging brain cells years before clinical symptoms appear. Unlike large amyloid plaques, which can be monitored via conventional PET scans, these oligomers are 'virtually invisible' to standard diagnostic tools, posing a major challenge to the medical world.
Addressing this challenge, a research team from the Department of Chemistry at Bar-Ilan University led by Professor Shai Rahimipour successfully created a series of specific cyclic peptides. This innovation works by selectively binding to amyloid-beta oligomers without interfering with large amyloid plaques. When labeled with radioactive or fluorescent substances, these compounds allow experts to visualize these toxic protein clusters directly in brain tissue.
In testing using mouse models, this molecular probe-based technology effectively demonstrated that these oligomers aggressively disrupt mitochondrial function, the nerve cells' powerhouses. This disruption occurs long before signs of inflammation appear, providing new insight into pathological mechanisms long hidden from current medical diagnostic methods.
These findings are considered to have crucial implications for evaluating current anti-amyloid therapies, such as Lecanemab and Donanemab. With the ability to accurately detect the presence of oligomers, future clinicians can monitor treatment efficacy with greater precision, rather than relying solely on the presence of plaques. This opens up opportunities for much earlier medical interventions to improve the quality of life for Alzheimer's patients worldwide.
